公开(公告)号：US20230381232A1

公开(公告)日：2023-11-30

申请号：US18158770

申请日：2023-01-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

CPC classification number: A61K35/17 ,  C07K14/70539 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/162 ,  C07K14/70517 ,  C07K14/70589 ,  C07K14/70564 ,  C12N5/0638 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C12N5/0636 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20210177898A1

公开(公告)日：2021-06-17

申请号：US17025607

申请日：2020-09-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20200147135A1

公开(公告)日：2020-05-14

申请号：US16616087

申请日：2018-05-24

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Peggy A. THOMPSON ,  Kevin R. WEBSTER

IPC: A61K35/17 ,  A61K31/4355 ,  A61K45/06 ,  A61K31/343 ,  A61P35/00

Abstract: The present disclosure provides compositions and methods for improving an antitumor response against non-inflamed solid tumors. Methods of this disclosure include use of an eIF4A inhibitor to promote infiltration of antitumor lymphocytes into a non inflamed solid tumor. Methods of treating cancer associated with a non-inflamed solid tumor are also provided.

公开(公告)号：US20220378821A1

公开(公告)日：2022-12-01

申请号：US17624504

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Kevin R. WEBSTER ,  Gary CHIANG

IPC: A61K35/13 ,  C12N15/10 ,  A61K31/519

Abstract: The present disclosure provides methods for the treatment of a subject having BRAF-mutated cancer cells comprising administering an effective amount of an eIF4E inhibitor, which may be optionally used in combination with other therapies, such as RAF inhibitors. Furthermore, BRAF mutational status can be used to select for patients that would clinically benefit from eIF4E inhibition, such as patient with BRAF-mutated cancer cells that are resistant to RAF kinase inhibitors.

公开(公告)号：US20180353545A1

公开(公告)日：2018-12-13

申请号：US15989098

申请日：2018-05-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K14/73 ,  C07K14/16

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.